Emerging treatments
Sodium-glucose cotransporter-2 (SGLT2) inhibitors
SGLT2 inhibitors have been proposed as a novel treatment of SIADH as they increase urinary glucose excretion with concomitant osmotic diuresis. In one trial of patients with SIADH treated with fluid restriction, use of empagliflozin had a larger increase in plasma sodium levels compared to placebo.[34]
Use of this content is subject to our disclaimer